Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBIT Margin: 2019-2025

Historic EBIT Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -120.30%.

  • BridgeBio Pharma's EBIT Margin rose 689837.00% to -120.30% in Q3 2025 from the same period last year, while for Sep 2025 it was -172.39%, marking a year-over-year increase of 7759.00%. This contributed to the annual value of -267.22% for FY2024, which is 626153.00% up from last year.
  • Per BridgeBio Pharma's latest filing, its EBIT Margin stood at -120.30% for Q3 2025, which was up 0.95% from -121.45% recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's EBIT Margin registered a high of 19,953.49% during Q4 2021, and its lowest value of -38,200.00% during Q3 2022.
  • Over the past 3 years, BridgeBio Pharma's median EBIT Margin value was -3,854.61% (recorded in 2023), while the average stood at -4,465.75%.
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's EBIT Margin was 12,445,267bps (2021), while the steepest drop was 3,881,206bps (2021).
  • Quarterly analysis of 5 years shows BridgeBio Pharma's EBIT Margin stood at 19,953.49% in 2021, then crashed by 2,686,430bps to -6,910.80% in 2022, then slumped by 325,630bps to -10,167.11% in 2023, then soared by 632,442bps to -3,842.69% in 2024, then surged by 689,837bps to -120.30% in 2025.
  • Its EBIT Margin stands at -120.30% for Q3 2025, versus -121.45% for Q2 2025 and -89.49% for Q1 2025.